oh dear
For the quarter ended March 31, 2024, AVITA Medical now expects commercial revenue to be in the range of US$11.0 million to US$11.3 million. This range is below the previously provided revenue guidance of US$14.8 million to US$15.6 million. The revision in guidance is attributable to a slower-than-expected conversion rate of new accounts for our expanded label of full-thickness skin defects.
Don't consider selling before profitability, page-246
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.99 |
Change
0.330(12.4%) |
Mkt cap ! $185.9M | |||
| Open | High | Low | Value | Volume |
| $3.04 | $3.17 | $2.95 | $5.283M | 1.752M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5991 | $2.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.00 | 12281 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.99 |
Change
0.330 ( 12.2 %) |
||||
| Open | High | Low | Volume | ||
| $3.10 | $3.10 | $2.95 | 117225 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| AVH (ASX) Chart |